Saturday 17 October 2026
Export ZBIO’s income statement to Excel — free account
Zenas BioPharma, Inc.
ZBIO Healthcare Biotechnology
Zenas BioPharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, up 100.0% from fiscal 2024. In the quarter to June 2026, EPS fell 41.6% and free cash flow fell 37.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
24.67
0.73
−2.87%
Follow ZBIO
Zenas BioPharma, Inc. (ZBIO) P/E ratio
Zenas BioPharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 2.3× (June 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2025 | 1.5× | — |
| Sep 2023 | 0.0× | — |
Against its own ten years
Low 0.0×
High 2.3×
Ten-year median
0.0×
Current reading's percentile
63
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OCUL Ocular Therapeutix, Inc. compare | n/m |
| ZBIO Zenas BioPharma, Inc. | n/m |
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| STOK Stoke Therapeutics, Inc. compare | n/m |
| BHVN Biohaven Ltd. compare | n/m |
| SEPN Septerna, Inc. compare | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| NUVB Nuvation Bio Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)